Key facts
- This page summarizes Joel Solomon Zev Schneider's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Mar 2022, 17:12.
Joel Solomon Zev Schneider - 14 Mar 2022 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- SLDB
- Reported as of
- 14 Mar 2022
- Net transaction value
- -$33,554
- SEC form
- 4
- Accepted by SEC
- 15 Mar 2022, 17:12:38 UTC
- Prior SEC filing
- 31 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Erin P. Brennan as attorney-in-fact for Joel Solomon Zev Schneider
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joel Solomon Zev Schneider filed Form 4 for Solid Biosciences Inc. (SLDB) on 15 Mar 2022.
Change
- Previous filing in this sequence was filed on 31 Jan 2022.
- Current net transaction value: -$33,554.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLDB
transaction
Common Stock
Sale
- Transaction value
- $16,755
- Shares
- -15,232
- Change %
- -5.7%
- Price
- $1.10
- Shares after
- 251,542
- Date
- 14 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2
SLDB
transaction
Common Stock
Sale
- Transaction value
- $16,799
- Shares
- -15,272
- Change %
- -6.1%
- Price
- $1.10
- Shares after
- 236,270
- Date
- 14 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
Footnote F2
Reflects a correction as to the number of securities previously reported in Column 5 of Table I due to an arithmetical error.